IGC News & Events

IGC Pharma announced that on April 9, it received authorization in Colombia to synthesize, formulate, and conduct development activities involving psilocybin at its research and development facility in Bogota. The authorization, granted under the oversight of the Fondo Nacional de Estupefacientes, provides IGC Pharma with a regulated capability to work with psilocybin, positioning the Company within an expanding area of scientific and investor interest. The Company believes it is among a limited number of organizations in Colombia with this type of authorization. This capability allows the Company to evaluate potential applications of psilocybin, for example in neuropsychiatric symptoms associated with dementia, including depression and anxiety, conditions affecting a large portion of Alzheimer's patients and representing a significant and underserved market opportunity

IGC Pharma announced the activation of a new clinical trial site at Tandem Clinical Research A Prolerity Network Site in Metairie, Louisiana, for the Company's ongoing Phase 2 CALMA clinical trial evaluating IGC-AD1 for agitation in Alzheimer's dementia. "We are pleased to welcome Tandem Clinical Research as a new clinical partner in the CALMA trial," said Ram Mukunda, CEO of IGC Pharma. "With enrollment now over 70% complete, expanding to this highly qualified investigational site with strong neurological expertise strengthens the trial's geographic reach, and enhances patient access. We look forward to working closely with Dr. Traylor and her team."

IGC Pharma announced a strategic 12-part national media partnership with New to The Street. The collaboration is designed to enhance IGC Pharma's visibility across both institutional and retail investor audiences through a coordinated, multi-channel media strategy. The campaign will include long-form televised interviews, national television commercial distribution, digital amplification, and high-visibility outdoor placements in key financial markets. As part of the initiative, IGC Pharma will be featured on New to The Street's sponsored programming on Fox Business and Bloomberg Television. The campaign will also be amplified through digital channels reaching a combined audience of more than 4.45M YouTube subscribers, as well as through outdoor billboard placements in Times Square and the New York City Financial District, and earned media distribution across major U.S. broadcast affiliates.